Skip to content
Disclosery

ACORN CAPITAL ADVISORS, LLC

Follow

13F filer, CIK 2054410, NEW YORK, NY

ACORN CAPITAL ADVISORS, LLC reported $196,993,688 across 20 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-17. Its ten largest share positions make up 87.67% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001636587-25-000060

Period
2025-09-30
Reported value
$197M
Holdings
20
Top 10 weight
87.67%
New
1
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
JSPRnew+1,382,640$3.29M
CRDFadded+553,317$1.14M
X4 PHARMACEUTICALS INCadded+119,619$409K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
Y-mAbs Therapeutics Incexited-3,418,995-$15.4M
MURAL ONCOLOGY PUB LTD COexited-653,779-$1.61M
VYNEreduced-150,000-$51K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001636587-25-000060, largest first. % of portfolio is the value over $196,993,688, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,131,501 shares; 2025Q1: 1,131,501 shares; 2025Q2: 1,131,501 shares; 2025Q3: 1,131,501 shares 1,131,501$45.6M23.14%0Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,516,303 shares; 2025Q1: 1,516,303 shares; 2025Q2: 1,259,749 shares; 2025Q3: 1,259,749 shares 1,259,749$25.1M12.76%0Timeline
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,940,052 shares; 2025Q1: 3,940,052 shares; 2025Q2: 4,131,299 shares; 2025Q3: 4,131,299 shares 4,131,299$21.9M11.14%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,001,048 shares; 2025Q1: 2,144,844 shares; 2025Q2: 2,144,844 shares; 2025Q3: 2,144,844 shares 2,144,844$19.6M9.96%0Timeline
TERNTERNS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,971,264 shares; 2025Q1: 1,971,264 shares; 2025Q2: 1,971,264 shares; 2025Q3: 1,971,264 shares 1,971,264$14.8M7.52%0Timeline
CADLCANDEL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,939,644 shares; 2025Q1: 2,152,252 shares; 2025Q2: 2,580,517 shares; 2025Q3: 2,580,517 shares 2,580,517$13.2M6.68%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 643,381 shares; 2025Q1: 643,382 shares; 2025Q2: 643,382 shares; 2025Q3: 643,382 shares 643,382$10.2M5.16%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,439,674 shares; 2025Q1: 1,439,674 shares; 2025Q2: 2,839,674 shares; 2025Q3: 2,839,674 shares 2,839,674$7.81M3.96%0Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,279,800 shares; 2025Q1: 1,279,800 shares; 2025Q2: 1,752,115 shares; 2025Q3: 1,752,115 shares 1,752,115$7.62M3.87%0Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 779,498 shares; 2025Q1: 779,498 shares; 2025Q2: 779,498 shares; 2025Q3: 779,498 shares 779,498$6.88M3.49%0Timeline
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 734,393 shares; 2025Q1: 734,394 shares; 2025Q2: 734,394 shares; 2025Q3: 734,394 shares 734,394$4.31M2.19%0Timeline
CRDFCARDIFF ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,442,308 shares; 2025Q1: 1,442,308 shares; 2025Q2: 1,408,767 shares; 2025Q3: 1,962,084 shares 1,962,084$4.04M2.05%+553,317Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 590,508 shares; 2025Q2: 595,744 shares; 2025Q3: 595,744 shares 595,744$3.68M1.87%0Timeline
BCABBIOATLA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,032,046 shares; 2025Q1: 4,032,046 shares; 2025Q2: 4,835,111 shares; 2025Q3: 4,835,111 shares 4,835,111$3.34M1.69%0Timeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,382,640 shares 1,382,640$3.29M1.67%newTimeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,147,052 shares; 2025Q1: 1,139,363 shares; 2025Q2: 1,139,363 shares; 2025Q3: 1,139,363 shares 1,139,363$2.16M1.1%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 803,425 shares; 2025Q1: 803,425 shares; 2025Q2: 803,425 shares; 2025Q3: 803,425 shares 803,425$1.59M0.81%0Timeline
X4 PHARMACEUTICALS INCX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 7,310,650 shares; 2025Q1: 7,310,650 shares; 2025Q2: 153,730 shares; 2025Q3: 273,349 shares 273,349$935K0.47%+119,619
ACRVACRIVON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 405,237 shares; 2025Q1: 405,237 shares; 2025Q2: 405,237 shares; 2025Q3: 405,237 shares 405,237$733K0.37%0Timeline
VYNEVYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 456,970 shares; 2025Q1: 785,938 shares; 2025Q2: 736,572 shares; 2025Q3: 586,572 shares 586,572$199K0.1%-150,000Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
Y-mAbs Therapeutics IncY-mAbs Therapeutics Inc3,418,995$15.4Mshares
MURAL ONCOLOGY PUB LTD COMURAL ONCOLOGY PUB LTD CO653,779$1.61Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001636587-25-000060 base2025-11-17acceptance time not in the bulk data set